HSBC Holdings
TGTX icon

HSBC Holdings’s TG Therapeutics TGTX Stock Holding History

HSBC Holdings’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,200
Closed -$1.23M – 3123
2025
Q2 		$1.23M Hold
34,200
– – ﹤0.01% 1700
2025
Q1 		$1.35M Sell
34,200
-2,300
-6% -$77.4K ﹤0.01% 1619
2024
Q4 		$1.1M Buy
36,500
+500
+1% +$14.3K ﹤0.01% 1746
2024
Q3 		$842K Buy
36,000
+6,000
+20% +$131K ﹤0.01% 1771
2024
Q2 		$539K Sell
30,000
-9,000
-23% -$144K ﹤0.01% 1937
2024
Q1 		$593K Buy
39,000
+17,500
+81% +$279K ﹤0.01% 2018
2023
Q4 		$367K Buy
+21,500
New +$250K ﹤0.01% 2190
2023
Q3 		– Sell
-33,000
Closed -$796K – 2847
2023
Q2 		$796K Buy
33,000
+19,500
+144% +$504K ﹤0.01% 1802
2023
Q1 		$198K Buy
+13,500
New +$205K ﹤0.01% 2397
2022
Q2 		– Sell
-2,000
Closed -$19K – 3443
2022
Q1 		$19K Buy
+2,000
New +$23.1K ﹤0.01% 3236
2021
Q4 		– Sell
-6,800
Closed -$226K – 3352
2021
Q3 		$226K Buy
6,800
+4,600
+209% +$142K ﹤0.01% 2715
2021
Q2 		$85K Sell
2,200
-19,100
-90% -$750K ﹤0.01% 2863
2021
Q1 		$1.03M Sell
21,300
-47,900
-69% -$2.3M ﹤0.01% 1589
2020
Q4 		$3.6M Buy
69,200
+28,200
+69% +$953K ﹤0.01% 1145
2020
Q3 		$1.1M Buy
41,000
+11,000
+37% +$253K ﹤0.01% 1507
2020
Q2 		$584K Buy
+30,000
New +$483K ﹤0.01% 1737
2020
Q1 		– Sell
-98,000
Closed -$1.07M – 3018
2019
Q4 		$1.07M Buy
98,000
+75,000
+326% +$570K ﹤0.01% 1807
2019
Q3 		$129K Buy
23,000
+2,400
+12% +$16.7K ﹤0.01% 2948
2019
Q2 		$178K Buy
20,600
+600
+3% +$4.54K ﹤0.01% 2578
2019
Q1 		$161K Buy
+20,000
New +$108K ﹤0.01% 2593
2018
Q4 		– Sell
-31,300
Closed -$175K – 2715
2018
Q3 		$175K Buy
31,300
+1,000
+3% +$11.4K ﹤0.01% 2446
2018
Q2 		$398K Buy
+30,300
New +$417K ﹤0.01% 2159

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HSBC Holdings's TGTX Position: Q1 2026 in Review

HSBC Holdings reduced its TG Therapeutics (TGTX) stake by 27% in Q1 2026, selling an estimated $1.18M and leaving 106,344 shares worth $3.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

HSBC Holdings first reported a position in TGTX in Q2 2018 and has held it in 17 quarters since. The position peaked at $4.37M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • HSBC Holdings held 106,344 shares of TG Therapeutics worth $3.56M as of Q1 2026.
  • HSBC Holdings sold 39,743 TG Therapeutics shares in Q1 2026, an estimated $1.18M.
  • TG Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1286 holding.
  • HSBC Holdings first reported a position in TG Therapeutics in Q2 2018 and has held it in 17 quarters since.
  • HSBC Holdings's TG Therapeutics position peaked at $4.37M in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.